Your browser doesn't support javascript.
loading
Dapagliflozin reduces plasma concentration of plasminogen activator inhibitor-1 in patients with heart failure with preserved ejection fraction and type 2 diabetes.
Dziewierz, Artur; Zabojszcz, Michal; Natorska, Joanna; Slusarczyk-Dolecka, Magdalena; Kuleta, Martyna; Siudak, Zbigniew.
Afiliação
  • Dziewierz A; Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
  • Zabojszcz M; Department of Cardiology and Cardiovascular Interventions, University Hospital, Kraków, Poland
  • Natorska J; Department of Internal Medicine and Cardiology, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  • Slusarczyk-Dolecka M; Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
  • Kuleta M; Center for Research and Innovative Technology, John Paul II Hospital, Kraków, Poland
  • Siudak Z; Department of Internal Medicine and Cardiology, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Pol Arch Intern Med ; 132(12)2022 12 21.
Article em En | MEDLINE | ID: mdl-36520466
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Insuficiência Cardíaca Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Insuficiência Cardíaca Idioma: En Ano de publicação: 2022 Tipo de documento: Article